Updates are available Correction dated 2022-04-21
Click to view Correction: https://doi.org/10.1038/s41591-022-01818-y
-
Authors
Tseng, Hung Fu https://orcid.org/0000-0001-6184-6534
Ackerson, Bradley K.
Luo, Yi https://orcid.org/0000-0001-8990-2470
Sy, Lina S. https://orcid.org/0000-0003-2762-9266
Talarico, Carla A.
Tian, Yun
Bruxvoort, Katia J.
Tubert, Julia E.
Florea, Ana
Ku, Jennifer H.
Lee, Gina S. https://orcid.org/0000-0002-7554-9116
Choi, Soon Kyu
Takhar, Harpreet S.
Aragones, Michael
Qian, Lei
-
Funding
Funding for this research was provided by:
Moderna, Inc.
- License Information
-
More Information
Article History
Received: 21 January 2022
Accepted: 17 February 2022
First Online: 21 February 2022
Change Date: 21 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01818-y
Competing interests
: All authors have completed the International Committee of Medical Journal Editors uniform disclosure form at and declare the following: H.F.T., B.K.A., Y.L., L.S.S., Y.T., J.E.T., A.F., J.H.K., G.S.L., S.K.C., H.S.T., M.A. and L.Q. are employees of Kaiser Permanente Southern California, which has been contracted by Moderna, Inc. to conduct this study. K.J.B. is an adjunct investigator at Kaiser Permanente Southern California. C.A.T. is an employee of and a shareholder in Moderna, Inc. H.F.T. received funding from GlaxoSmithKline and Seqirus unrelated to this manuscript. H.F.T. also served on advisory boards for Janssen and Pfizer. B.K.A. received funding from GlaxoSmithKline, Dynavax, Seqirus, Pfizer and Genentech for work unrelated to this study and has served on advisory boards for GlaxoSmithKline. Y.L. received funding from GlaxoSmithKline, Seqirus and Pfizer unrelated to this manuscript. L.S.S. received funding from GlaxoSmithKline, Dynavax and Seqirus unrelated to this manuscript. Y.T. received funding from GlaxoSmithKline unrelated to this manuscript. K.J.B. received funding from GlaxoSmithKline, Dynavax, Pfizer, Gilead and Seqirus unrelated to this manuscript. J.E.T. received funding from Pfizer unrelated to this manuscript. A.F. received funding from Pfizer, GlaxoSmithKline and Gilead unrelated to this manuscript. J.H.K. received funding from GlaxoSmithKline unrelated to this manuscript. G.S.L. received funding from GlaxoSmithKline unrelated to this manuscript. S.K.C. received funding from Pfizer and the Pancreatic Cancer Action Network unrelated to this manuscript. H.S.T. received funding from GlaxoSmithKline, Pfizer, ALK and Wellcome unrelated to this manuscript. M.A. received funding from Pfizer unrelated to this manuscript. L.Q. received funding from GlaxoSmithKline and Dynavax unrelated to this manuscript.
